| | | | | | | | | | |
|
| |
|
| Dockets Entered
On October 30, 2006
|
|
|
|
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
|
|
| 2003D-0478
|
| Guidance on Marketed Unapproved Drugs Compliance Policy Guide
|
|
|
|
|
| 2004D-0198
|
| Guidance for Industry: Acceptable Full-Length Donor History Questionnaire and Accompanying Materials for Use in Screening Human Donors of Blood and Blood Components
|
|
|
|
|
| 2004P-0349
|
| Action on Products containing added Mercury
|
|
|
|
|
| 2005P-0411
|
| Seeking FDA Actions to Counter Flagrant Violations of the Law by Pharmacies Compounding Bio-Identical Hormone Replacement Therapy Drugs
|
|
|
|
|
| 2006D-0331
|
| Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors; Exception from Informed Consent Requirements for Emergency Research
|
|
|
|
|
| 2006D-0344
|
| Guidance for Industry on Drug Interaction Studies--Study Design, Data Analysis, and Implications for Dosing and Labeling
|
|
|
|
|
| 2006D-0413
|
| Guidance for Industry: Blue Bird Medicated Feed Labels
|
|
|
|
|
| 2006N-0352
|
| Comments Relating to the September 6 & 7, 2006 Joint Panel Meeting on Dental Amalgam
|
|
|
|
|
| 2006N-0420
|
| Agency Information Collection Activities; Proposed Collection; Comment Request; Orphan Drugs
|
|
|
|
|
| 2006P-0390
|
| Order the Church of Scientology to clearly disclose the potential health hazards inherent in the use of the E-meter and Scientology's practice of "auditing"
|
|
|
|
|
| 2006P-0394
|
| Revise the labeling requirements for eggs sold in the United States
|
|
|
|
|
| 2006P-0417
|
| Permit the Filing of an ANDA Suitability for Doxycycline Monohydrate Tablets
|
|
|
|
|
| 2006P-0442
|
| Determine that Wyeth Pharmaceuticals, Inc. discontinued its previously-approved formulation of the Reference Listed Drug Zosyn (piperacillin and tazobactam for injection), 40.5 gram pharmacy bulk via
|
|
|
|
|
|
|
|
|
|
|
| 2003D-0478
|
| Guidance on Marketed Unapproved Drugs Compliance Policy Guide
|
|
|
|
|
| EC 35
|
| Mr. david lowe
|
| Vol #:
|
| 5
|
|
|
|
|
| 2004D-0198
|
| Guidance for Industry: Acceptable Full-Length Donor History Questionnaire and Accompanying Materials for Use in Screening Human Donors of Blood and Blood Components
|
|
|
|
|
| NAD 2
|
| FDA
|
| Vol #:
|
| 1
|
|
|
|
|
| 2004P-0349
|
| Action on Products containing added Mercury
|
|
|
|
|
| EC 23
|
| Mr. Dave Lowe
|
| Vol #:
|
| 4
|
|
|
|
|
| 2005P-0411
|
| Seeking FDA Actions to Counter Flagrant Violations of the Law by Pharmacies Compounding Bio-Identical Hormone Replacement Therapy Drugs
|
|
|
|
|
| C 18171
|
| C. Cooper
|
| Vol #:
|
| 196
|
|
|
|
|
| C 18172
|
| P. Burke
|
| Vol #:
|
| 196
|
|
|
|
|
| C 18173
|
| I. Calhoun
|
| Vol #:
|
| 196
|
|
|
|
|
| C 18174
|
| P. McNulty
|
| Vol #:
|
| 196
|
|
|
|
|
| C 18175
|
| C. Pearce
|
| Vol #:
|
| 196
|
|
|
|
|
| C 18176
|
| J. Schwand
|
| Vol #:
|
| 196
|
|
|
|
|
| C 18177
|
| J. Halonen
|
| Vol #:
|
| 196
|
|
|
|
|
| 2006D-0331
|
| Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors; Exception from Informed Consent Requirements for Emergency Research
|
|
|
|
|
| EC 46
|
| Mr. Leonard Glantz
|
| Vol #:
|
| 2
|
|
|
|
|
| EC 47
|
| Association of American Medical Colleges
|
| Vol #:
|
| 2
|
|
|
|
|
| 2006D-0344
|
| Guidance for Industry on Drug Interaction Studies--Study Design, Data Analysis, and Implications for Dosing and Labeling
|
|
|
|
|
| EC 3
|
| Ordway Research Institute Drug Development Center
|
| Vol #:
|
| 1
|
|
| | | | | | | | |
|
| |
|
| EC 122
|
| Dental Care
|
| Vol #:
|
| 3
|
|
|
|
|
| EC 123
|
| Dental Care
|
| Vol #:
|
| 3
|
|
|
|
|
| EC 124
|
| Dental Care
|
| Vol #:
|
| 3
|
|
|
|
|
| EC 125
|
| Dental Care
|
| Vol #:
|
| 3
|
|
|
|
|
| EC 126
|
| Dental Care
|
| Vol #:
|
| 3
|
|
|
|
|
| 2006N-0420
|
| Agency Information Collection Activities; Proposed Collection; Comment Request; Orphan Drugs
|
|
|
|
|
| N 1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
|
|
| 2006P-0390
|
| Order the Church of Scientology to clearly disclose the potential health hazards inherent in the use of the E-meter and Scientology's practice of "auditing"
|
|
|
|
|
| EC 11
|
| Mr. Peter Finnegan
|
| Vol #:
|
| 1
|
|
|
|
|
| 2006P-0394
|
| Revise the labeling requirements for eggs sold in the United States
|
|
|
|
|
| EC 365
|
| Ms. debbie trujillo
|
| Vol #:
|
| 2
|
|
|
|
|
| EC 366
|
| Ms. mars green
|
| Vol #:
|
| 2
|
|
|
|
|
| EC 367
|
| Mrs. carol battocchio
|
| Vol #:
|
| 2
|
|
|
|
|
| EC 368
|
| Mrs. kim beck
|
| Vol #:
|
| 2
|
|
|
|
|
| EC 369
|
| Ms. Lauren Panos
|
| Vol #:
|
| 2
|
|
|
|
|
| EC 370
|
| Ms. Marilyn Wilson
|
| Vol #:
|
| 2
|
|
|
|
|
| EC 371
|
| Ms. Julie Hoffheins
|
| Vol #:
|
| 2
|
|
|
|
|
| EC 372
|
| Mr. Jonathan Krieger
|
| Vol #:
|
| 2
|
|
|
|
|
| 2006P-0417
|
| Permit the Filing of an ANDA Suitability for Doxycycline Monohydrate Tablets
|
|
|
|
|
| EC 1
|
| Mr. david lowe
|
| Vol #:
|
| 1
|
|
|
|
|
| 2006P-0442
|
| Determine that Wyeth Pharmaceuticals, Inc. discontinued its previously-approved formulation of the Reference Listed Drug Zosyn (piperacillin and tazobactam for injection), 40.5 gram pharmacy bulk via
|
|
|
|
|
|
|
|
|
| ACK 1
|
| FDA/DDM to Orchid Healthcare
|
| Vol #:
|
| 1
|
|
|
|
|
| CP 1
|
| Orchid Healthcare
|
| Vol #:
|
| 1
|
|
